Jandeleit-Dahm KA - Search Results

1

Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Watson AM, Olukman M, Koulis C, Tu Y, Samijono D, Yuen D, Lee C, Behm DJ, Cooper ME, Jandeleit-Dahm KA, Calkin AC, Allen TJ. Watson AM, et al. Diabetologia. 2013 May;56(5):1155-65. doi: 10.1007/s00125-013-2837-9. Epub 2013 Jan 24. Diabetologia. 2013. PMID: 23344731

2

Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis.

Thannickal VJ, Jandeleit-Dahm K, Szyndralewiez C, Török NJ. Thannickal VJ, et al. J Cell Mol Med. 2023 Feb;27(4):471-481. doi: 10.1111/jcmm.17649. Epub 2023 Jan 19. J Cell Mol Med. 2023. PMID: 36658776 Free PMC article. Review.

3

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA. Lassila M, et al. J Am Soc Nephrol. 2004 Aug;15(8):2125-38. doi: 10.1097/01.ASN.0000133025.23732.46. J Am Soc Nephrol. 2004. PMID: 15284298

4

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Jandeleit-Dahm KA, et al. J Hypertens. 2005 Mar;23(3):463-73. doi: 10.1097/01.hjh.0000160198.05416.72. J Hypertens. 2005. PMID: 15716683 Review.

5

Advanced-glycation end products in insulin-resistant states.

Soldatos G, Cooper ME, Jandeleit-Dahm KA. Soldatos G, et al. Curr Hypertens Rep. 2005 Apr;7(2):96-102. doi: 10.1007/s11906-005-0081-5. Curr Hypertens Rep. 2005. PMID: 15748532 Review.

6

Lipids and diabetic renal disease.

Cooper ME, Jandeleit-Dahm KA. Cooper ME, et al. Curr Diab Rep. 2005 Dec;5(6):445-8. doi: 10.1007/s11892-005-0053-9. Curr Diab Rep. 2005. PMID: 16316596 Review.

7

Direct antiatherosclerotic effects of PPAR agonists.

Jandeleit-Dahm KA, Calkin A, Tikellis C, Thomas M. Jandeleit-Dahm KA, et al. Curr Opin Lipidol. 2009 Feb;20(1):24-9. doi: 10.1097/mol.0b013e32831f1b18. Curr Opin Lipidol. 2009. PMID: 19133407 Review.

8

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.

Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. Watson AM, et al. Diabetologia. 2010 Jan;53(1):192-203. doi: 10.1007/s00125-009-1540-3. Epub 2009 Oct 28. Diabetologia. 2010. PMID: 19862499

9

Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

Koïtka A, Cao Z, Koh P, Watson AM, Sourris KC, Loufrani L, Soro-Paavonen A, Walther T, Woollard KJ, Jandeleit-Dahm KA, Cooper ME, Allen TJ. Koïtka A, et al. Diabetologia. 2010 Mar;53(3):584-92. doi: 10.1007/s00125-009-1619-x. Epub 2009 Dec 3. Diabetologia. 2010. PMID: 19957160

10

The endothelin system and endothelin receptor antagonists.

Jandeleit-Dahm KA, Watson AM. Jandeleit-Dahm KA, et al. Curr Opin Nephrol Hypertens. 2012 Jan;21(1):66-71. doi: 10.1097/MNH.0b013e32834dde48. Curr Opin Nephrol Hypertens. 2012. PMID: 22123210 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page